NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
Refinitivน้อยกว่า 1 นาทีในการอ่าน
Neuropace Inc 
NPCE:
NEUROPACE INC: REAFFIRMS ITS PREVIOUSLY ISSUED FULL-YEAR 2025 FINANCIAL GUIDANCE
NEUROPACE INC - COMPLETES PRIMARY ENDPOINT ANALYSIS FOR IDIOPATHIC GENERALIZED EPILEPSY STUDY
NEUROPACE INC - STUDY MEETS 12-WEEK POST-IMPLANT SAFETY ENDPOINT
NEUROPACE INC - PRELIMINARY DATA SHOWS FAVORABLE SEIZURE REDUCTION RATES FOR RNS SYSTEM
NEUROPACE - PRIMARY EFFECTIVENESS ENDPOINT NOT STATISTICALLY SIGNIFICANT IN OVERALL POPULATION
เข้าสู่ระบบหรือสร้างบัญชีฟรีถาวรเพื่ออ่านข่าวนี้